Current and Emerging Second‐Generation Triptans in Acute Migraine Therapy: A Comparative Review

@article{Deleu2000CurrentAE,
  title={Current and Emerging Second‐Generation Triptans in Acute Migraine Therapy: A Comparative Review},
  author={Dirk Deleu and Yolande Hanssens},
  journal={The Journal of Clinical Pharmacology},
  year={2000},
  volume={40}
}
Sterile neurogenic inflammation within cephalic tissue, involving vasodilation and plasma protein extravasation, has been proposed as a pathophysiological mechanism in acute migraine. The action of 5‐hydroxytryptamine (5‐HT1B/1D) agonists—so‐called triptans—on receptors located in meningeal arteries (5‐HT1B) and trigeminovascular fiber endings (5‐HT1D) has an inhibitory effect on this neurogenic inflammation. Recently, a series of second‐generation 5‐HT1B/1D agonists (almotriptan, eletriptan… 
Is selective 5‐HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy?
TLDR
This review will be particularly focussed on the similarities and differences between the triptans and the ditans, their proposed sites of action, side effects and their cardiovascular risk profile.
Eletriptan
TLDR
Eletriptan (40 and 80 mg) has been shown to be effective as early as 30 min after administration and well tolerated when compared to placebo and showed the most favorable cost-effectiveness profile when compared with other agents in its class.
Migraine in the era of precision medicine.
TLDR
Therapies targeting on the neuropeptids and genes may be helpful in the precision medicine of migraineurs and 5-hydroxytryptamine (5-HT) receptor agonists and calcitonin gene-related peptide (CGRP) receptor antagonists have demonstrated efficacy in the acute specific treatment of migraine attacks.
Targeting the 5-HT1B/1D and 5-HT1F receptors for acute migraine treatment.
TLDR
The development of agents targeting the 5-HT1B/1D and 5- HT1F receptors and the clinical evidence supporting the use of these agents for acute migraine treatment are summarized.
Mechanisms of action of the 5-HT1B/1D receptor agonists.
TLDR
The high affinity of the triptans for 5-HT(1B/1D) receptors and their favorable pharmacologic properties contribute to the beneficial effects of these drugs, including rapid onset of action, effective relief of headache and associated symptoms, and low incidence of adverse effects.
Therapies in development for the treatment of migraine
  • H. Mucke
  • Medicine
    Expert opinion on investigational drugs
  • 2002
While oral formulations of agonists at the serotonin (5-HT) receptor subdivisions 5-HT1B/1D – the ‘triptan’ class of drugs – dominate the market for migraine therapy and while still more triptans are
Triptans and CNS Side-Effects
TLDR
If CNS sideeffects are a clinically relevant concern in the individual patient, use of a triptan with a low incidence of CNS side-effects may offer the potential for earlier initiation of treatment and more effective outcomes.
Triptans in migraine. A review of side effects, improvement and recurrence
TLDR
A quick but exhaustive schedule type is established, merely in order to standardize all data obtained through a few fixed parameters and therefore directly comparable on the currently available compounds.
Reassessing the contraindication of zolmitriptan and serotonin reuptake inhibitors: an evidence‐based pharmacotherapeutic case report
TLDR
As the contraindication between zolmitriptan and SSRIs is theoretically, not empirically, based and the opportunity to coprescribe these agents is likely to be frequent, a re-evaluation of the contraineddication is justified.
Renal Infarction During the Use of Rizatriptan and Zolmitriptan: Two Case Reports
TLDR
Although both rizatriptan and zolmitriptan are effective in the treatment of migraine and cluster headaches, they may induce peripheral vasospasm leading to renal infarction.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 164 REFERENCES
Acute migraine therapy: the newer drugs
TLDR
A central action now proved experimentally in animals and in humans for 5-HT1B/D agonists such as zolmitriptan may be advantageous for the antimigraine efficacy, but it could also increase sedation.
Receptor specificity and trigemino‐vascular inhibitory actions of a novel 5‐HT1B/1D receptor partial agonist, 311C90 (zolmitriptan)
TLDR
The receptor specificity of the drug and its actions on trigeminal‐evoked plasma protein extravasation into the dura mater of the anaesthetized guinea‐pig is described and the inability of 5‐ HT1B/1D agonists to achieve the same maximum as the endogenous agonist 5‐HT is explained by the additional presence of5‐HT2A receptors.
Zolmitriptan, a 5‐HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose‐range finding study
TLDR
The dose response data suggest that lower doses of oral zolmitriptan would also offer significant efficacy, and the most commonly reported adverse events were asthenia, dizziness, paraesthesia and feelings of heaviness.
Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents.
TLDR
In vitro and in vivo pharmacological properties, clinical efficacy, drug interactions, and adverse effects are evaluated and compared to the gold standard in the treatment of acute migraine, sumatriptan.
Pre-clinical pharmacology of zolmitriptan (Zomig™; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine
  • G. Martin
  • Medicine
    Cephalalgia : an international journal of headache
  • 1997
TLDR
A novel preclinical profile not only distinguishes zolmitriptan from sumatriptan, but raises intriguing questions about the clinical relevance of a dual action.
Sumatriptan in the treatment of migraine
TLDR
Evidence from animal and human studies suggests that sumatriptan constricts dural vessels and inhibits neuropeptide release from trigeminal nerve endings by activating 5-HT1 receptors, a 5- HT1 receptor agonist, is effective in treating acute migraine attacks.
The Long‐term Tolerability and Efficacy of Oral Zolmitriptan (Zomig, 31X90) in the Acute Treatment of Migraine. An International Study
This international open‐label study evaluated the tolerability and efficacy of zolmitriptan (Zomig®, 311C90), a selective 5‐HT1B/1D receptor agonist in the long‐term treatment of multiple migraine
Rizatriptan has central antinociceptive effects against durally evoked responses.
TLDR
Rizatriptan has central activity which may contribute to its efficacy against migraine headache and may also have activity at 5-HT(1B/1D) receptors within the central nervous system (CNS) that contributes to its antimigraine effects.
Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5‐hydroxy‐tryptamine (5‐HT1B/1D) receptors
TLDR
It is established that naratriptan acts on central trigeminal neurones since sagittal sinus stimulation activates axons within the tentorial nerve and there are no inhibitory effects mediated within the trigemINAL ganglion.
5‐HT1 receptors in migraine pathophysiology and treatment
TLDR
“Breakthrough of peripheral suppressive effect” with an ongoing “central migraine generator”, rather than the occurrence of a new attack, seems to be the most likely underlying mechanism for headache recurrence, and in a minority of, possibly predisposed, patients, use of sumatriptan may induce increase of attack frequency.
...
1
2
3
4
5
...